NEW YORK, Dec. 17, 2008 (GLOBE NEWSWIRE) -- Lescarden Inc. (OTCBB:LCAR), announced today that it has signed an agreement with the Philusa Corporation of Quezon City, Republic of the Philippines. Under the terms of the agreement, Philusa will have exclusive rights to the marketing and distribution of Lescarden's Repliderm(r) Burn Relief line of consumer products for cuts, minor burns and wounds. The Companies are completing the required marketing application to the Filipino Bureau of Food and Drug (BFAD) regulatory authorities. It is anticipated that the marketing of Repliderm will commence by the second quarter of 2009.
William Luther, President and CEO of Lescarden, stated, "The introduction of the Repliderm line to consumers in the Philippines is an important step forward. This will be the first time a Catrix-based skin care product will be available to the mass retail market. We are pleased to be working with Philusa, which has established itself as the leader in the marketing and distribution of health and personal care products in the Philippines."
About Repliderm
Repliderm features the same key ingredient found in Lescarden's Catrix(r) Wound Dressing which has been shown in extensive clinical testing to be an effective aid in the healing of wounds that are resistant to the healing process.
The Catrix wound dressing has been approved by the United States FDA for the management of first and second degree burns as well as decubitus ulcers, venous stasis and diabetic ulcers and post-radiation dermatitis. Catrix based skin care products have earned a strong reputation among dermatologists and plastic surgeons for healing skin following cosmetic procedures.
About Philusa
Philusa Inc., a subsidiary of the privately-owned Mercury Group of Companies, is the leading distributor of drug and personal care products in the Philippines. Included in their distribution network is the Mercury Drug chain with over 800 stores country-wide in addition to a network of over 3,000 independent distribution outlets. For more information please visit www.philusa.com.ph or www.mercurydrug.com.
About Lescarden Inc.
Lescarden, Inc., is a biotechnology company dedicated to the development and marketing of natural, biologic therapies for the chronic wound care, dermatology and osteoarthritis markets. For more information please contact the Company at 212-687-1050 or visit www.catrix.com. Lescarden, Inc. is a publicly traded company. (OTCBB:LCAR)